抗微生物抗体反应与未来克罗恩病发病风险独立相关
该关联独立于肠道屏障功能标志物、亚临床炎症及遗传风险,且部分通过临床前肠道炎症介导(42%)。
要点
- 基线抗微生物抗体阳性总和≥2与未来克罗恩病风险独立相关(调整OR 6.5)。
- 关联独立于肠道屏障功能、粪便钙卫蛋白、CRP及多基因风险评分。
- 高抗体总和对未来克罗恩病的效应部分(42%)通过临床前肠道炎症介导。
核心结论
- 抗微生物抗体反应增强与未来克罗恩病发病风险相关,且独立于肠道屏障功能异常、亚临床炎症及克罗恩病相关遗传风险。
研究设计与样本
- 嵌套病例对照研究,样本来自加拿大克罗恩病遗传环境微生物项目前瞻性随访的健康一级亲属。
- 未来发生克罗恩病者77例,按年龄、性别、随访时长和地理位置1:4匹配仍健康对照307例。
- 入组时采用Prometheus酶联免疫吸附试验检测6种微生物抗原的血清抗体反应,并计算阳性抗体总和(AS)。
主要发现
- 调整肠道屏障功能标志物、粪便钙卫蛋白、C反应蛋白及克罗恩病多基因风险评分后,该关联仍显著。
- 在诊断前3年以上入组的受试者中,该关联仍显著。
- 因果中介分析显示,高AS对未来克罗恩病发病的效应部分(42%)通过临床前肠道炎症介导。
临床怎么用
- 在克罗恩病一级亲属中,基线抗微生物抗体阳性总和≥2提示未来发病风险升高,可辅助风险分层。
- 该风险信号独立于肠道屏障功能、亚临床炎症及遗传风险,支持抗微生物抗体反应作为克罗恩病早期病前事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Altered host immune reactivity to microbial antigens is hypothesized to trigger the onset of Crohn's disease (CD). We aimed to assess whether increased serum anti-microbial antibody response in asymptomatic first-degree relatives (FDRs) of CD patients is an independent risk factor for future CD development. METHODS: We measured host serum antibody response to 6 microbial antigens at enrollment (Prometheus enzyme-linked immunosorbent assay test: anti-Saccharomyces cerevisiae antibodies immunoglobulin A/immunoglobulin G, anti-OmpC, anti-A4-Fla2, anti-FlaX, anti-CBir1) and derived the sum of positive antibodies (AS). We used samples at enrollment of prospectively followed healthy FDRs from a nested case-control cohort of the Crohn's and Colitis Canada Genetics Environment Microbial Project. Those who later developed CD (n = 77) were matched 1:4 by age, sex, follow-up duration, and geographic location with control FDRs remaining healthy (n = 307). To address our research aims, we fitted a multivariable conditional logistic regression model and performed causal mediation analysis. RESULTS: High baseline AS (≥2) (43% of cases, 11% of controls) was associated with higher risk of developing CD (adjusted odds ratio, 6.5; 95% confidence interval, 3.4-12.7; P < .001). Importantly, this association remained significant when adjusted for markers of gut barrier function, fecal calprotectin, C-reactive protein, and CD-polygenic risk score, and in subjects recruited more than 3 years before diagnosis. Causal mediation analysis showed that the effect of high AS on future CD development is partially mediated (42%) via preclinical gut inflammation. CONCLUSIONS: Our results suggest that increased anti-microbial antibody responses are associated with risk of future development of CD, independent of biomarkers of abnormal gut barrier function, subclinical inflammation, and CD-related genetic risks. This suggests that anti-microbial antibody responses are an early predisease event in the development of CD.
引用
- Lee SH, Turpin W, Espin-Garcia O, et al. Anti-Microbial Antibody Response is Associated With Future Onset of Crohn's Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk. Gastroenterology. 2021. PMID: 34293299. doi:10.1053/j.gastro.2021.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。